Bioxytran OTC Stock Insiders
| BIXT Stock | USD 0.09 0.01 12.92% |
Bioxytran employs about 2 people. The company is managed by 3 executives with a total tenure of roughly 7 years, averaging almost 2.0 years of service per executive, having 0.67 employees per reported executive. Breaking down Bioxytran's management performance can provide insight into the firm performance.
| David Platt CEO President CEO, Director |
Bioxytran |
Bioxytran Management Team Effectiveness
The company has return on total asset (ROA) of (7.0399) % which means that it has lost $7.0399 on every $100 spent on assets. This is way below average. Bioxytran's management efficiency ratios could be used to measure how well Bioxytran manages its routine affairs as well as how well it operates its assets and liabilities.Bioxytran Workforce Comparison
Bioxytran is number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 88.0. Bioxytran holds roughly 2.0 in number of employees claiming about 2.27% of equities under Health Care industry.
Bioxytran Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bioxytran insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bioxytran's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Bioxytran insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Alan Hoberman over a year ago Acquisition by Alan Hoberman of 77721 shares of Bioxytran subject to Rule 16b-3 | ||
Alan Hoberman over a year ago Acquisition by Alan Hoberman of 77721 shares of Bioxytran subject to Rule 16b-3 | ||
David Platt over a year ago Acquisition by David Platt of 5824741 shares of Bioxytran subject to Rule 16b-3 | ||
David Platt over a year ago Bona fide gift to David Platt of 92000 shares of Bioxytran subject to Section 16 | ||
David Platt over a year ago Acquisition by David Platt of 6763562 shares of Bioxytran subject to Rule 16b-3 | ||
Alan Hoberman over a year ago Acquisition by Alan Hoberman of 50000 shares of Bioxytran subject to Rule 16b-3 | ||
David Platt over a year ago Bona fide gift to David Platt of 411300 shares of Bioxytran subject to Section 16 | ||
Alan Hoberman over a year ago Acquisition by Alan Hoberman of 20000 shares of Bioxytran subject to Rule 16b-3 |
Bioxytran Notable Stakeholders
A Bioxytran stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bioxytran often face trade-offs trying to please all of them. Bioxytran's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bioxytran's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| David Platt | President CEO, Director | Profile | |
| CMA CPA | Treasurer CFO | Profile | |
| Michael BS | Chief Officer | Profile |
About Bioxytran Management Performance
The success or failure of an entity such as Bioxytran often depends on how effective the management is. Bioxytran management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bioxytran management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bioxytran management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts. Bioxytran operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.
The data published in Bioxytran's official financial statements typically reflect Bioxytran's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Bioxytran's quantitative information. For example, before you start analyzing numbers published by Bioxytran accountants, it's essential to understand Bioxytran's liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Please note, the imprecision that can be found in Bioxytran's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bioxytran. Check Bioxytran's Beneish M Score to see the likelihood of Bioxytran's management manipulating its earnings.
Bioxytran Workforce Analysis
Traditionally, organizations such as Bioxytran use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bioxytran within its industry.Bioxytran Manpower Efficiency
Return on Bioxytran Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 2M | |
| Net Loss Per Executive | 1.3M |
Additional Tools for Bioxytran OTC Stock Analysis
When running Bioxytran's price analysis, check to measure Bioxytran's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioxytran is operating at the current time. Most of Bioxytran's value examination focuses on studying past and present price action to predict the probability of Bioxytran's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioxytran's price. Additionally, you may evaluate how the addition of Bioxytran to your portfolios can decrease your overall portfolio volatility.